Acute kidney rejection after anti-SARS-CoV-2 virus-vectored vaccine-case report.

Autor: Vnučák M; Transplantation Centre, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia., Graňák K; Transplantation Centre, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia. granak.k@gmail.com., Beliančinová M; Transplantation Centre, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia., Jeseňák M; Department of Children and Adolescents, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia., Macháleková KK; Department of Pathology, St. Elizabeth Cancer Institute Hospital, Bratislava, Slovakia., Benko J; 1st Department of Internal Diseases, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia., Samoš M; 1st Department of Internal Diseases, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia., Dedinská I; Transplantation Centre, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin, Slovakia.
Jazyk: angličtina
Zdroj: NPJ vaccines [NPJ Vaccines] 2022 Mar 02; Vol. 7 (1), pp. 30. Date of Electronic Publication: 2022 Mar 02.
DOI: 10.1038/s41541-022-00445-5
Abstrakt: COVID-19 infection remains a threat to the health systems of many countries. Potential success in the fight against the COVID-19 pandemic is the vaccination of high-risk groups, including patients with end-stage kidney disease (ESKD) and after solid organ transplantation (SOT). Immunosuppression in kidney transplant recipients can also reduce the immunogenicity of SARS-CoV-2 vaccines (varied by vaccine platform), available data suggest that they are efficacious in approximately 50-70%, compared to non-transplant situations. In this paper, we present a newly developed acute humoral and cellular rejection with acute allograft failure and need of hemodialysis 14 days after administration of the adenovirus vectored SARS-CoV-2 vaccine (AstraZeneca; CHADOx1, AZD1222). This occurred in a patient who previously had an asymptomatic COVID-19 infection. Case reports of acute allograft rejection after vaccination against SARS-CoV-2 can help stratify risk groups of patients who develop hyperimmune reactions. However, it is also possible that those with a previous mild primary COVID-19 infection may also develop acute allograft rejections upon COVID-19 re-infection.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: